Changes of microbiome profile during nivolumab treatment in NSCLC patients.-Reference-Cited by-同舟云学术

Changes of microbiome profile during nivolumab treatment in NSCLC patients.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:e15020-e15020
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Botticelli Andrea¹,Putignani Lorenza²,Zizzari Ilaria³,Del Chierico Federica²,Reddel Sofia²,DI Pietro Francesca¹,Quagliarello Andrea²,Onesti Concetta Elisa¹,Raffaele Giusti⁴,Mazzuca Federica⁵,Nuti Marianna³,Marchetti Paolo⁵

Affiliation:

1. Department of Clinical and Molecular Medicine, Sapienza University Sant' Andrea Hospital, Rome, Italy;

2. Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy;

3. Department of Experimental Medicine, Sapienza University Policlinico Umberto 1, Rome, Italy;

4. Sant'Andrea Hospital, Rome, Italy;

5. S. Andrea Hospital, Sapienza University of Rome, Rome, Italy;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.e15020

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome;Gut Microbes;2024-05-08

2. Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review;Cell Death & Disease;2024-04-09

3. Microbiome bacterial influencers of host immunity and response to immunotherapy;Cell Reports Medicine;2024-04

4. Causal effects of gut microbiota in the development of lung cancer and its histological subtypes: A Mendelian randomization study;Thoracic Cancer;2024-01-12

5. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target;Experimental Hematology & Oncology;2023-09-28